Cell-free synthesis of influenza virus-like particles (VLPs) as prototyping platform for vaccine development and variant characterization
Cell-free synthesis of influenza virus-like particles (VLPs) as prototyping platform for vaccine development and variant characterization
批准号:
10648472
负责人:
Irina V Novikova
金额:
$8.07万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-04-01 至 2025-03-31
关键词:
AddressAntigensArchitectureBiomanufacturingBiomedical EngineeringCapsidCell Culture TechniquesCell-Free SystemCellsCryo-electron tomographyCryoelectron MicroscopyDisease OutbreaksDrug Delivery SystemsElectron MicroscopyEnsureFutureGenerationsGerm CellsGlycoproteinsGoalsHepatitis B VirusHeterogeneityHeterophile AntigensHumanIndividualInfluenzaInfluenza A Virus, H5N1 SubtypeInfluenza A Virus, H7N9 SubtypeInfluenza A Virus, H9N2 SubtypeInfluenza A virusLearningMass Spectrum AnalysisMicrosomesMorphologyMutationNegative StainingPichiaPopulationProductionProtein BiosynthesisProteinsRecombinantsResolutionSafetySamplingSurfaceSystemTechnologyTestingVaccine ResearchVaccinesVariantViral GenomeVirusVirus-like particleWheatcostdensityflexibilityfuture pandemicglycosylationimmunogenicinfluenza virus straininfluenza virus vaccineinfluenzavirusmanufacturepandemic diseaseparticleprophylacticprotein expressionprototyperecombinant virusresearch and developmentresponseself assemblystructural biologythree dimensional structuretomographyvaccine developmentvaccine platformvirology
中文摘要
摘要
缺乏预防性和低成本的流感疫苗,生产速度缓慢
让我们对下一次全球大流行毫无准备。重组病毒样颗粒
(VLP)疫苗为我们提供了解决这些困难的独特机会,但它们的
重组合成策略仅限于细胞培养生产,这是有挑战的。
例如有限的吞吐量和获得的产品的体系结构异构性。在这个项目中,
我们的目标是将小麦胚芽无细胞蛋白表达平台与具有活性的微生物体相结合
不同来源(包括人类)合成糖基化流感病毒样颗粒(VLP)。
这些颗粒将进一步接受详细的形态和成分检查,使用
电子显微镜和天然质谱学来了解所获得的结构
并了解其组装和组成变化的机制。高-
分辨率断层扫描将被用来确定具有最大抗原的最佳VLP候选
入住率,从而最大限度地提高疫苗效率。我们假设这种方法将是
适用于稳定和精简的流感VLP,并将提供更多
灵活性和对其架构异构性的控制,并最终作为快速
流感疫苗研发的原型平台。目前的项目也将通知我们
关于使用这种方法进行病毒学和糖蛋白合成的效用。
英文摘要
SUMMARY
The absence of prophylactic and low-cost influenza vaccines along with slow production rate
makes us unprepared for the next pandemic outbreak worldwide. Recombinant virus-like particles
(VLPs) vaccines provide us with unique opportunities to address these difficulties, but their
recombinant synthesis strategies are limited to cell culture production, which has its challenges
such as limited throughput and architectural heterogeneity of the obtained products. In this project,
we aim to combine wheat germ cell-free protein expression platform with active microsomes of
different origins (including human) to synthesize glycosylated influenza virus-like particles (VLPs).
These particles will further undergo detailed morphological and compositional examination using
electron microscopy and native mass spectrometry to understand the architecture of obtained
products and understand the mechanisms of their assembly and composition variability. High-
resolution tomography will be utilized to determine the best VLP candidates with maximal antigen
occupancy and thus maximal vaccine efficiency. We hypothesize that this approach will be
suitable for a stable and streamlined generation of Influenza VLPs and will offer much more
flexibility and control over their architectural heterogeneity and eventually serve as a rapid
prototyping platform for influenza vaccine development. The current project will also inform us
about the utility of using such approaches for virology and for glycoprotein synthesis in general.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: